Art. -Nr.: HY-10627

GW3965

Name: GW3965
Brand: MedChemExpress
SKU: HY-10627
Price: 72.00 USD
Availability: InStock
Rating: 5 (29 reviews)

29 Cited Publications

Kundenbewertung

Based on 29 publication(s) in Google Scholar

GW3965 is a potent, selective liver X receptor (LXR) agonist with EC₅₀s of 190 nM and 30 nM for hLXRα and hLXRβ, respectively.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit : 99.80%
CAS. Nr.: 405911-09-3
Formel: C₃₃H₃₁ClF₃NO₃
Molecular Weight:582.05

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

GW3965 Chemical Structure

CAS. Nr.: 405911-09-3

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (29)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

GW3965 is a potent, selective liver X receptor (LXR) agonist with EC₅₀s of 190 nM and 30 nM for hLXRα and hLXRβ, respectively^[1]^[2]^[3].

IC₅₀ & Target

EC50: 190 nM (hLXRα), 30 nM (hLXRβ)

Cellular Effect

Cell Line	Type	Value	Description	References
CHO	EC₅₀	410 nM Compound: 2, GW-3965	Agonist activity at human LXR beta receptor expressed in CHO cells by reporter assay Agonist activity at human LXR beta receptor expressed in CHO cells by reporter assay	[PMID: 17034119]
CHO-K1	EC₅₀	0.42 μM Compound: 2, GW3965	Agonist activity at Gal4-tagged LXRbeta (unknown origin) expressed in CHOK1 cells after 24 hrs by luciferase reporter gene assay Agonist activity at Gal4-tagged LXRbeta (unknown origin) expressed in CHOK1 cells after 24 hrs by luciferase reporter gene assay	[PMID: 25677664]
CHO-K1	EC₅₀	1.3 μM Compound: 2, GW3965	Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells after 24 hrs by luciferase reporter gene assay Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells after 24 hrs by luciferase reporter gene assay	[PMID: 25677664]
COS-7	EC₅₀	0.015 μM Compound: GW-3965	Activation of LXRbeta co-transfected in COS7 cells with RXRalpha by reporter transactivation assay Activation of LXRbeta co-transfected in COS7 cells with RXRalpha by reporter transactivation assay	[PMID: 17416521]
COS-7	EC₅₀	0.015 μM Compound: GW-3965	Agonist activity at human LXRbeta receptor transfected in COS7 cells after 16 hrs by reporter transactivation assay Agonist activity at human LXRbeta receptor transfected in COS7 cells after 16 hrs by reporter transactivation assay	[PMID: 17587573]
COS-7	EC₅₀	100 % Compound: GW-3965	Agonist activity at human LXRbeta receptor transfected in COS7 cells after 16 hrs by reporter transactivation assay relative to GW-3965 Agonist activity at human LXRbeta receptor transfected in COS7 cells after 16 hrs by reporter transactivation assay relative to GW-3965	[PMID: 17587573]
HepG2	EC₅₀	2002 nM Compound: 2, GW-3965	Effect on triglyceride accumulation in human HepG2 cells Effect on triglyceride accumulation in human HepG2 cells	[PMID: 18973288]
HepG2	EC₅₀	210 nM Compound: 2, GW-3965	Effect on SREBP1c gene expression in human HepG2 cells Effect on SREBP1c gene expression in human HepG2 cells	[PMID: 18973288]
Huh-7	EC₅₀	0.31 μM Compound: 2, GW-3965	Agonist activity at human recombinant LXRbeta ligand binding domain in human HuH7 cells co-transfected with fused Gal4-DBD by transactivation assay Agonist activity at human recombinant LXRbeta ligand binding domain in human HuH7 cells co-transfected with fused Gal4-DBD by transactivation assay	[PMID: 18973288]
Huh-7	EC₅₀	0.66 μM Compound: 2, GW-3965	Agonist activity at human recombinant LXRalpha ligand binding domain in human HuH7 cells co-transfected with fused Gal4-DBD by transactivation assay Agonist activity at human recombinant LXRalpha ligand binding domain in human HuH7 cells co-transfected with fused Gal4-DBD by transactivation assay	[PMID: 18973288]
Platelet	IC₅₀	30 nM Compound: GW3965	Inhibition of collagen-induced platelet aggregation in human platelet suspension preincubated for 10 mins followed by collagen stimulation by light transmission-based assay Inhibition of collagen-induced platelet aggregation in human platelet suspension preincubated for 10 mins followed by collagen stimulation by light transmission-based assay	[PMID: 32463237]
RAW264.7	EC₅₀	29 nM Compound: 2	Induction of [3H]cholesterol efflux in mouse RAW264.7 cells loaded with acetylated-LDL after 24 hrs Induction of [3H]cholesterol efflux in mouse RAW264.7 cells loaded with acetylated-LDL after 24 hrs	[PMID: 19717304]
SH-SY5Y	EC₅₀	0.13 μM Compound: 3, GW-3965	Agonist activity at human LXRbeta expressed in human SH-SY5Y cells co-transfected with Gal4-LBD after 24 hrs by luciferase reporter gene assay Agonist activity at human LXRbeta expressed in human SH-SY5Y cells co-transfected with Gal4-LBD after 24 hrs by luciferase reporter gene assay	[PMID: 19264481]
SH-SY5Y	EC₅₀	0.31 μM Compound: 3, GW-3965	Agonist activity at human LXRalpha expressed in human SH-SY5Y cells co-transfected with Gal4-LBD after 24 hrs by luciferase reporter gene assay Agonist activity at human LXRalpha expressed in human SH-SY5Y cells co-transfected with Gal4-LBD after 24 hrs by luciferase reporter gene assay	[PMID: 19264481]
THP-1	EC₅₀	0.01 μM Compound: GW-3965	Induction of cholesterol efflux in THP1 cells after 18 hrs Induction of cholesterol efflux in THP1 cells after 18 hrs	[PMID: 17416521]
THP-1	EC₅₀	0.01 μM Compound: GW-3965	Induction of cholesterol efflux in THP1 cells Induction of cholesterol efflux in THP1 cells	[PMID: 17587573]
THP-1	EC₅₀	0.027 μM Compound: 1, GW-3965	Agonist activity at GAL-linked human LXRbeta expressed in THP1 cells assessed as stimulation of co-activator recruitment by FRET assay Agonist activity at GAL-linked human LXRbeta expressed in THP1 cells assessed as stimulation of co-activator recruitment by FRET assay	[PMID: 17665897]
THP-1	EC₅₀	0.097 μM Compound: 1, GW-3965	Agonist activity at GAL-linked human LXRalpha expressed in THP1 cells assessed as stimulation of coactivator recruitment by FRET assay Agonist activity at GAL-linked human LXRalpha expressed in THP1 cells assessed as stimulation of coactivator recruitment by FRET assay	[PMID: 17665897]
THP-1	EC₅₀	31 nM Compound: 2, GW-3965	Stimulation of [3H]cholesterol efflux in human THP1 foam cells loaded with ac-LDL Stimulation of [3H]cholesterol efflux in human THP1 foam cells loaded with ac-LDL	[PMID: 18973288]
THP-1	EC₅₀	434 nM Compound: 2, GW-3965	Effect on ABCA1 gene expression in human differentiated THP1 cells Effect on ABCA1 gene expression in human differentiated THP1 cells	[PMID: 18973288]
THP-1	IC₅₀	20 nM Compound: 2, GW-3965	Antiinflammatory activity against human THP1 cells assessed as inhibition of LPS-stimulated IL6 production after 6 hrs by ELISA Antiinflammatory activity against human THP1 cells assessed as inhibition of LPS-stimulated IL6 production after 6 hrs by ELISA	[PMID: 18800767]
U-87MG ATCC	IC₅₀	3.65 μM Compound: GW3965	Antiproliferative activity against human U87 cells overexpressing EGFR variant III measured after 7 days by CCK8 assay Antiproliferative activity against human U87 cells overexpressing EGFR variant III measured after 7 days by CCK8 assay	[PMID: 32248003]

In Vitro

GW3965 promotes GBM cell death in vitro with enhanced efficacy in EGFRvIII-expressing tumor cells. GW3965 up-regulates expression of the cholesterol transporter gene ABCA1 and the E3 ubiquitin ligase IDOL and reduces LDLR levels^[2]. LXR ligands inhibits platelet aggregation and calcium mobilization stimulated by collagen or CRP. GW3965 (1 or 5 μM) displays a minor inhibitory effect on fibrinogen binding and P-selectin exposure, when platelets are stimulated with 1 μg/mL CRP. But using higher concentrations of GW3965 (10 μM) or T0901317 (40 μM), the levels of fibrinogen and P-selectin on the platelet surface are reduced^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

GW3965 induces an increase of neuroactive steroids in the spinal cord, the cerebellum and the cerebral cortex of STZ-rats, but not in the CNS of non-pathological animals. GW3965 treatment induces an increase of dihydroprogesterone in the spinal cord of diabetic animals in association with an increase of myelin basic protein expression^[1]. GW3965 (40 mg/kg, p.o.) strongly induces ABCA1 expression and reduces LDLR expression, and this is accompanied by 59% inhibition of tumor growth, and a 25-fold increase in GBM cell apoptosis in vivo^[2]. GW3965 (2 mg/kg, i.v.) increases bleeding time and modulated platelet thrombus formation in vivo^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 405911-09-3
Appearance Solid
Molecular Weight 582.05
Formel C₃₃H₃₁ClF₃NO₃
Color White to off-white
SMILES

ClC1=C(C(F)(F)F)C=CC=C1CN(CC(C2=CC=CC=C2)C3=CC=CC=C3)CCCOC4=CC(CC(O)=O)=CC=C4
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (29)

All Cell Imaging/StainingCell Proliferation/Viability AssayApoptosis AnalysisOthersWBRT-PCRIHC

Sort by:

Journal Impact Factor

Nat Commun

PROTAC repurposing uncovers a noncanonical binding surface that mediates chemical degradation of nuclear receptors. [Abstract]

2025 Nov 6;16(1):9805. PMID: 41198675
Theranostics

LXR activation potentiates sorafenib sensitivity in HCC by activating microRNA-378a transcription. [Abstract]

2020 Jul 11;10(19):8834-8850. PMID: 32754282

GW3965 purchased from MedChemExpress. Usage Cited in: Theranostics. 2020 Jul 11;10(19):8834-8850. [Abstract]

Flow cytometry showed the combination of sorafenib and GW3965 (1, 2 μM) could induce apoptosis in Huh7-SR and HCCLM3-SR.

GW3965 purchased from MedChemExpress. Usage Cited in: Theranostics. 2020 Jul 11;10(19):8834-8850. [Abstract]

Colony-formation efficiency showed the emergency of Huh7-SR coloines which treated with Sorafenib and GW3965 (1, 2 μM) was less than that treated with Sorafenib alone.

GW3965 purchased from MedChemExpress. Usage Cited in: Theranostics. 2020 Jul 11;10(19):8834-8850. [Abstract]

WB showed IGF1R were upregulated in combination along with their common downstream target pERK/p-AKT and combination treatment also could induce apoptosis treated with GW3965 (1, 2 μM).

GW3965 purchased from MedChemExpress. Usage Cited in: Theranostics. 2020 Jul 11;10(19):8834-8850. [Abstract]

The impact of Sorafenib, GW3965 and the combination therapy on cell viability in Huh7-SR and HCCLM3-SR cells were determined by CCK8 assay.

GW3965 purchased from MedChemExpress. Usage Cited in: Theranostics. 2020 Jul 11;10(19):8834-8850. [Abstract]

Immunohistochemistry showed Sorafenib and GW3965 (30 mg/kg) combination therapy could suppress HCC proliferation and IGF1R level in vivo.
MedComm (2020)

Cholesterol 25-Hydroxylase Enhances Myeloid-Derived Suppressor Cell (MDSC) Immunosuppression via the Stimulator of Interferon Genes (STING)-Tank-Binding Kinase 1 (TBK1)-Receptor-Interacting Protein Kinase 3 (RIPK3) Pathway in Colorectal Cancer. [Abstract]

2025 Sep 27;6(10):e70411. PMID: 41020041
Sci Adv

ZMYND8 is a master regulator of 27-hydroxycholesterol that promotes tumorigenicity of breast cancer stem cells. [Abstract]

2022 Jul 15;8(28):eabn5295. PMID: 35857506
Cell Death Differ

The lipogenic LXR-SREBF1 signaling pathway controls cancer cell DNA repair and apoptosis and is a vulnerable point of malignant tumors for cancer therapy. [Abstract]

2020 Aug;27(8):2433-2450. PMID: 32144382
Environ Sci Technol

Impact of 1,2-Bis (2,4,6-Tribromophenoxy) Ethane on Liver Metabolism and Intestinal Health in Zebrafish: Role of the Liver X Receptor. [Abstract]

2025 Apr 25. PMID: 40277015
Cancer Lett

Myeloid-derived suppressor cells deficient in cholesterol biosynthesis promote tumor immune evasion. [Abstract]

2023 Jun 28:564:216208. PMID: 37150500
Environ Int

Lipid metabolic disruption: A potential mechanistic pathway for 2,4,6-tribromophenol-induced neurotoxicity in zebrafish. [Abstract]

2026 Jul:213:110355. PMID: 42288112
Environ Int

Cresyl diphenyl phosphate (a novel organophosphate ester) induces hepatic steatosis by directly binding to liver X receptor α: From molecule action to risk assessment. [Abstract]

2024 Dec:194:109168. PMID: 39612745

GW3965 purchased from MedChemExpress. Usage Cited in: Environ Int. 2024 Dec:194:109168. [Abstract]

Representative images of Oil red O straining of HepG2 cells after treated with different concentrations of GW3965 (0, 1, and 10 μM; 72 h).

GW3965 purchased from MedChemExpress. Usage Cited in: Environ Int. 2024 Dec:194:109168. [Abstract]

Total triglycerides (TG) and total cholesterol (T-CHO) contents of HepG2 cells after treated with GW3965 (1-10 μM; 72 h).

GW3965 purchased from MedChemExpress. Usage Cited in: Environ Int. 2024 Dec:194:109168. [Abstract]

Expression of the genes in HepG2 cells measured by qRT-PCR after treated with GW3965 (1-10 μM).
J Transl Med

Mitochondrial dysfunction fuels drug resistance in adult T-cell acute lymphoblastic leukemia. [Abstract]

2025 May 14;23(1):542. PMID: 40369632

GW3965 purchased from MedChemExpress. Usage Cited in: J Transl Med. 2025 May 14;23(1):542. [Abstract]

Control or Ethidium Bromide treated (100-200 ng/mL; 7 d) CCRF-CEM and MOLT-4 cells, were treated with the indicated concentrations of GW3965 (0.5-10 μM; 24 h) and the accumulation of P-gp and β-actin was visualized as above.
JHEP Rep

2026 May 5.
Brain Behav Immun

LXR-β regulates microglial efferocytosis and neuroinflammation in CPSP via STAT6 activation. [Abstract]

2025 Aug 21:106089. PMID: 40848997
Fundam Res

2026 Mar 12.
J Ethnopharmacol

Xiaoyan Lidan formula ameliorates cholecystitis by regulating cholesterol transportation and water permeability of the gall bladder through the activation of LXRβ. [Abstract]

2026 Apr 6:360:121150. PMID: 41485629
J Ethnopharmacol

QiShenYiQi pill inhibits atherosclerosis by promoting reverse cholesterol transport PPARγ-LXRα/β-ABCA1 pathway. [Abstract]

2023 Oct 28:315:116684. PMID: 37230281
J Am Heart Assoc

Protective Functions of Liver X Receptor α in Established Vulnerable Plaques: Involvement of Regulating Endoplasmic Reticulum-Mediated Macrophage Apoptosis and Efferocytosis. [Abstract]

2021 May 18;10(10):e018455. PMID: 33969692
Respir Res

Activation of LXR signaling ameliorates apoptosis of alveolar epithelial cells in Bronchopulmonary dysplasia. [Abstract]

2024 Nov 7;25(1):399. PMID: 39511537

GW3965 purchased from MedChemExpress. Usage Cited in: Respir Res. 2024 Nov 7;25(1):399. [Abstract]

MLE12 cells were cultured under normoxia (NOX) or hyperoxia (HYX) conditions with different doses of GW3965 (1-10 μM) for 24 h, and cell viability was determined by CCK-8 assays.

GW3965 purchased from MedChemExpress. Usage Cited in: Respir Res. 2024 Nov 7;25(1):399. [Abstract]

MLE12 cells were cultured under normoxia (NOX) or hyperoxia (HYX) conditions with different doses of GW3965 (1-15 μM) for 24 h, and detected relative mRNA expression of Abca1 normalized to Gapdh.

GW3965 purchased from MedChemExpress. Usage Cited in: Respir Res. 2024 Nov 7;25(1):399. [Abstract]

Representative pictures of MLE12 cells exposed to NOX or HYX for 24 h treated with or without 5 µM GW3965 stained by Filipin III and the quantification of the mean fluorescence intensity of Filipin III staining.
Int Immunopharmacol

Sirtuin 6 activator UBCS039 ameliorates hepatic lipogenesis through liver X receptor deacetylation. [Abstract]

2026 Jan 1;168(Pt 2):115878. PMID: 41265217
Biogerontology

Upregulation of LXRβ/ABCA1 pathway alleviates cochlear hair cell senescence of C57BL/6 J mice via reducing lipid droplet accumulation. [Abstract]

2025 Jan 31;26(2):49. PMID: 39890652
Bioconjug Chem

Targeted Delivery of LXR Agonist Using a Site-Specific Antibody-Drug Conjugate. [Abstract]

2015 Nov 18;26(11):2216-22. PMID: 25945727
Am J Physiol Endocrinol Metab

Liver X receptor-α activation enhances cholesterol secretion in lactating mammary epithelium. [Abstract]

2019 Jun 1;316(6):E1136-E1145. PMID: 30964702
Viruses

Pseudorabies Virus Inhibits Expression of Liver X Receptors to Assist Viral Infection. [Abstract]

2022 Mar 3;14(3):514. PMID: 35336921
Drug Metab Dispos

Synergistic hepatotoxicity of azithromycin and acetaminophen involves liver X receptor α-mediated metabolic dysregulation and endoplasmic reticulum stress. [Abstract]

2026 May 13. PMID: 42263432
Cytokine

Eliminating myeloid-derived suppressor cells alleviates immunosuppression and reduces susceptibility to secondary infections in a two-hit sepsis model. [Abstract]

2025 Jul:191:156955. PMID: 40339353
Immun Inflamm Dis

Liver X Receptor Activation Alleviates Hepatic Ischemia-Reperfusion Injury in Diabetes by Inhibiting NF-κB-NLRP3 Activation. [Abstract]

2025 Aug;13(8):e70243. PMID: 40778489
Vet Microbiol

The activation of liver X receptors in Madin-Darby bovine kidney cells and mice restricts infection by bovine viral diarrhea virus. [Abstract]

2024 Jan:288:109948. PMID: 38113573
SSRN

2025 Aug 13.
bioRxiv

2023 Mar 10.
Radboud University Nijmegen

2021 Mar.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (171.81 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.7181 mL

8.5903 mL

17.1807 mL

5 mM

0.3436 mL

1.7181 mL

3.4361 mL

10 mM

0.1718 mL

0.8590 mL

1.7181 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 5 mg/mL (8.59 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Cell Assay^[2]

Cells are seeded in 96 wells and are treated after 24 hours with different drugs indicated in each experiment in medium containing 1% FBS or lipoprotein deficient serum. Relative proliferation is determined using Cell Proliferation Assay Kit. Cells are incubated 1.5 hrs after adding tetrazolium salt WST-1 [2-(4-iodophenyl)-3- (4-nitrophenyl)-5-(2, 4-disulfo-phenyl)-2H-tetrazolium, monosodium salt] at 5% CO₂, 37ºC and the absorbance of the treated and untreated cells are measured using a microplate reader at 420 to 480 nm. Cells seeded in 12 well plates are counted using a hemocytometer, and dead cells are assessed using trypan blue exclusion assays.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[1]

Diabetes is induced in two-month-old male rats by a single i.p. injection of freshly prepared STZ (65 mg/kg) in 0.09 M citrate buffer, pH 4.8. Control animals are injected with 0.09 mol/L citrate buffer at pH 4.8. Hyperglycemia is confirmed 48 h after streptozotocin injection by measuring tail vein blood glucose levels using a glucometer OneTouch Ultra2. Only animals with mean plasma glucose levels over 300 mg/mL are classified as diabetic. Glycemia is also assessed before treatment with Ro5-4864 or GW3965 and before death. Two months after STZ injection, diabetic animals are treated once a week with Ro5-4864 (3 mg/kg) or GW3965 (50 mg/kg). Thus, they receive four subcutaneous injections in a month. Control diabetic rats receive 200 μL of vehicle (sesame oil). Four-month-old non-diabetic male rats are injected, following the same experimental schedule, with Ro5-4864, GW3965 or vehicle. Rats are killed 24 h after the last treatment.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (283 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Mitro, Nico., et al. LXR and TSPO as new therapeutic targets to increase the levels of neuroactive steroids in the central nervous system of diabetic animals. Neurochemistry International (2012), 60(6), 616-621. [Content Brief]

[2]. Guo, Deliang., et al. An LXR Agonist Promotes Glioblastoma Cell Death through Inhibition of an EGFR/AKT/SREBP-1/LDLR-Dependent Pathway. Cancer Discovery (2011), 1(5), 442-456.

[3]. Spyridon, Michael., et al. LXR as a novel antithrombotic target. Blood (2011), 117(21), 5751-5761. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.7181 mL	8.5903 mL	17.1807 mL	42.9516 mL
	5 mM	0.3436 mL	1.7181 mL	3.4361 mL	8.5903 mL
	10 mM	0.1718 mL	0.8590 mL	1.7181 mL	4.2952 mL
	15 mM	0.1145 mL	0.5727 mL	1.1454 mL	2.8634 mL
	20 mM	0.0859 mL	0.4295 mL	0.8590 mL	2.1476 mL
	25 mM	0.0687 mL	0.3436 mL	0.6872 mL	1.7181 mL
	30 mM	0.0573 mL	0.2863 mL	0.5727 mL	1.4317 mL
	40 mM	0.0430 mL	0.2148 mL	0.4295 mL	1.0738 mL
	50 mM	0.0344 mL	0.1718 mL	0.3436 mL	0.8590 mL
	60 mM	0.0286 mL	0.1432 mL	0.2863 mL	0.7159 mL
	80 mM	0.0215 mL	0.1074 mL	0.2148 mL	0.5369 mL
	100 mM	0.0172 mL	0.0859 mL	0.1718 mL	0.4295 mL

Bioz

Keywords

GW3965

29 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

GW3965

Publications Citing Use of MedChemExpress (MCE) GW3965